Aclarion Sees Triple-Digit Growth, $2.5M Buyback and Q4 2026 Trial Readout
ACON•Aclarion reported triple-digit annual growth in Nociscan adoption and anticipates an interim CLARITY trial readout in Q4 2026. The company also launched a $2.5 million share repurchase program, holds 64 issued and pending patents, and maintains a debt-free balance sheet with cash runway into the second half of 2027.
1. Conference Presentation
Aclarion will present at the Planet MicroCap Las Vegas conference on June 17, 2026 at 8:30 AM PT. Executive Chairman Jeff Thramann will lead the session at the Bellagio Resort & Hotel and host a Q&A for investors following the presentation.
2. Nociscan Adoption and Clinical Milestones
The Nociscan platform achieved triple-digit annual growth as more clinical workflows integrate its biomarkers and AI algorithms to pinpoint chronic low back pain. An interim readout from the ongoing CLARITY trial is expected in Q4 2026, marking a key regulatory and reimbursement milestone.
3. Financial Position and Share Buyback
Aclarion unveiled a $2.5 million share repurchase program to support its stock and signal confidence in value creation. The company operates debt-free with sufficient cash to fund operations into the second half of 2027, reinforcing its long-term growth strategy.
4. Patent Portfolio
The company strengthened its intellectual property with a new AI patent, bringing its total to 64 issued and pending worldwide. This expanded patent footprint underpins exclusivity for its MRS-based Nociscan diagnostics and augmented intelligence algorithms.
